Month: August 2024

CariGenetics: Innovating Genomic Sequencing with PromethION in Bermuda

Tonight, I watched the London Calling 2024 product demo. The title of the session was “From sample to insight: exploring human genomics with PromethION end-to-end sequencing solutions.” Rachel Rubinstein, a Technical Product Manager with ONT, was the moderator. They explained that with a single PromethION flow cell, you can obtain 100-200 Gbases of data and […]
Read more

Enhancing Acute Care in New Zealand Through Nanopore Sequencing

Justin O’Sullivan from the Liggins Institute at the University of Auckland in New Zealand presented at London 2024. The session’s title was “Establishing a nanopore sequencing facility for acute care in New Zealand.” They spoke about closing the borders during the pandemic. Being an island, they can control entrance and exit from the country more […]
Read more

Unveiling the Potential of Long-Read Sequencing in Newborn Screening

Tonight, I watched Cate Paschal from the Seattle Children’s Hospital. They spoke about “Exploration of long-read sequencing in the resolution of newborn screening.” This was a London Calling 2024 session. Paschal spoke about newborn screening as a diagnostic test for rare diseases. Paschal explained that Pompe disease is a glycogen storage disorder with a prevalence […]
Read more

HERRO: Haplotype-Aware Error Correction of Ultra-Long Nanopore Reads by Mile Sikic

Mile Sikic from the Genome Institute of Singapore spoke at London Calling 2024. The session’s title was “HERRO: haplotype-aware error correction of ultra-long nanopore reads.” Sikic noted that HERRO can be used for any type of Nanopore reads. They developed Racon seven years ago. Now, there are phased genomes, and the challenge is to maintain […]
Read more

Enhancing Biopharmaceutical Safety Through Sequencing

Thomas R. Kreil from Takeda Austria presented at London Calling 2024. The session title was “Pathogen safety in biopharma: sequencing to come.” Kreil began by noting that they do not want to detect viruses in biopharmaceuticals. For this, they use Adventitious Agent Testing (AAT): they search for cytopathic effects on cells. However, current methods are […]
Read more

Phylogenetics and Phylogeography of HIV: Insights from Big Events Research

Tetyana Vasylyeva from the University of California, Irvine, presented at London Calling 2024. The topic was “Informing infectious disease interventions with genomics during big events.” I was curious about the big events! This session was part of the Clinical & Biopharma Day on Friday, May 24, 2024. Vasylyeva studies phylogenetics, phylodynamics, and phylogeography of HIV! […]
Read more

Long-Read Sequencing for Rare Diseases: Clinical & Biopharma Day Highlights

The London Calling 2024 session I watched tonight was titled “Long-read sequencing for pathogenic and novel variation discovery in rare diseases.” Ahmad Abou Tayoun from the Al Jailila Children’s Specialty Hospital in the United Arab Emirates was the presenter. This session was part of the Clinical & Biopharma Day on Friday, May 24, 2024. They spoke about […]
Read more

Nanopore Sequencing in Clinical Settings: Canadian Transplant Innovations

The London Calling 2024 session I watched tonight is called “Precision immunology in transplant: paving the way to operational tolerance.” Karen Sherwood from The University of British Columbia presented the Genome Canada Transplant Consortium work. The group noticed that trying to match organs and recipients on a genetic level was complex. Using next-generation sequencing, HLA […]
Read more

Rapid Nephrogenomics for Thrombotic Microangiopathies: Significant Time Frame Improvements

Tonight I watched the London Calling session on “Rapid nephrogenomics for thrombotic microangiopathies.” Laurent Mesnard from Sorbonne University in France was the presenter. They defined thrombotic microangiopathies (TMA) as a group of rare diseases with similar manifestations. Early diagnosis of TMA is essential. It currently takes about three days to screen. The Regulator of Complement […]
Read more